Sugi Predict

Sugi Predict / Compounds / SCHEMBL3375718

SCHEMBL3375718

SCHEMBL3375718

CC(C)(C)OC(=O)NC(C(=O)O)C1CCC(F)(F)CC1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 3/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ PYGL P06737 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA7 P43166 1/20 0.38
▸ CTSS P25774 5/20 0.38
▸ CTSK P43235 5/20 0.38
▸ CTSL P07711 2/20 0.36
▸ ELANE P08246 1/20 0.36
▸ BTK Q06187 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CTSB P07858 1/20 0.35
▸ MMP13 P45452 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8356484 1.00 AAK1 (0.40) AAK1KMT2APYGLCYP2C9CA1
SCHEMBL29252902 0.92 KMT2A (0.38) AAK1KMT2APYGLCYP2C9CA1
SCHEMBL31094703 0.90 AAK1 (0.39) AAK1KMT2ACA1CA2CA7
SCHEMBL30953384 0.90 AAK1 (0.39) AAK1KMT2ACA1CA2CA7
SCHEMBL10174960 0.87 CA12 (0.40) AAK1KMT2ACA1CA2CA7
SCHEMBL31485567 0.87 AAK1 (0.41) AAK1KMT2ACA1CA2CA7
SCHEMBL15823887 0.87 CA12 (0.40) AAK1KMT2ACA1CA2CA7
SCHEMBL13210069 0.87 AAK1 (0.40) AAK1KMT2ACA1CA2CA7
SCHEMBL22126036 0.87 AAK1 (0.40) AAK1KMT2ACA1CA2CA7
SCHEMBL22143566 0.87 AAK1 (0.40) AAK1KMT2ACA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4143193-B1 IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2026-04-22 — — EP disclosed
US-12600728-B2 Interleukin-17 inhibitors NOVARTIS AG (CH) 2026-04-14 — — US disclosed
EP-4711365-A1 THIAZOLE DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2026-03-18 — — EP disclosed
US-12559496-B2 Imidazopyrimidines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2026-02-24 — — US disclosed
EP-3681875-B1 CYCLIC PEPTIDE ANTIBIOTICS HOFFMANN LA ROCHE (CH) 2026-01-14 — — EP disclosed
EP-4630115-A1 THERAPEUTIC COMPOUNDS Sanofi (FR) 2025-10-15 — — EP disclosed
US-20250197378-A1 SMALL MOLECULE MODULATORS OF IL-17 LEO PHARMA AS (DK) 2025-06-19 — — US disclosed
US-20250188040-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS INC 2025-06-12 — — US disclosed
CN-111148739-B Cyclic peptide antibiotics 豪夫迈·罗氏有限公司 2025-06-03 — — CN disclosed
US-20250171427-A1 THERAPEUTIC COMPOUNDS SANOFI (FR) 2025-05-29 — — US disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 — — US disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 — — US disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 — — US disclosed
WO-2009005677-A2 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2009-01-08 — — WO disclosed
US-20070232549-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION 2007-10-04 — — US disclosed
US-20070232549-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION 2007-10-04 — — US disclosed
US-7244721-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2007-07-17 — — US disclosed
US-20070032433-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. 2007-02-08 — — US disclosed
US-20070032433-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. 2007-02-08 — — US disclosed
WO-2003062265-A2 NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS SCHERING CORPORATION (US) 2003-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197378-A1 SMALL MOLECULE MODULATORS OF IL-17 IL17A, IL2, IL23R AAK1 3126/4885KMT2A 3693/4885PYGL 3914/4885
US-20070232549-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus HPN, TMPRSS15, VIP AAK1 3028/4885KMT2A 3449/4885PYGL 110/4885
US-20090186869-A1 Antiviral compounds MAVS, EIF2AK2, ZC3HAV1 AAK1 3098/4885KMT2A 3803/4885PYGL 2026/4885
US-12559496-B2 Imidazopyrimidines as modulators of IL-17 IL17A, IL2, IL23R AAK1 2838/4885KMT2A 3063/4885PYGL 4326/4885
US-20070032433-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus HPN, TMPRSS15, VIP AAK1 3028/4885KMT2A 3449/4885PYGL 110/4885
US-20250188040-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS RECQL, BLM, WRN AAK1 3889/4885KMT2A 2565/4885PYGL 825/4885
US-20250171427-A1 THERAPEUTIC COMPOUNDS IL17A, IL2, IL36G AAK1 4153/4885KMT2A 4255/4885PYGL 1591/4885
US-12600728-B2 Interleukin-17 inhibitors IL17A, IL2, IL1B AAK1 768/4885KMT2A 1852/4885PYGL 2659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.